Nothing Special   »   [go: up one dir, main page]

IL124309A - Aztidinylalkyl derivatives of the N-heterocyclic compounds, the process for their preparation and medicinal preparations containing them for the antagonists of tachycin - Google Patents

Aztidinylalkyl derivatives of the N-heterocyclic compounds, the process for their preparation and medicinal preparations containing them for the antagonists of tachycin

Info

Publication number
IL124309A
IL124309A IL12430996A IL12430996A IL124309A IL 124309 A IL124309 A IL 124309A IL 12430996 A IL12430996 A IL 12430996A IL 12430996 A IL12430996 A IL 12430996A IL 124309 A IL124309 A IL 124309A
Authority
IL
Israel
Prior art keywords
alkyl
compound
formula
cycloalkyl
alkoxy
Prior art date
Application number
IL12430996A
Other languages
English (en)
Hebrew (he)
Other versions
IL124309A0 (en
Original Assignee
Pfizer Res And Dev Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res And Dev Company filed Critical Pfizer Res And Dev Company
Priority to IL14532496A priority Critical patent/IL145324A0/xx
Publication of IL124309A0 publication Critical patent/IL124309A0/xx
Publication of IL124309A publication Critical patent/IL124309A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL12430996A 1996-01-05 1996-12-09 Aztidinylalkyl derivatives of the N-heterocyclic compounds, the process for their preparation and medicinal preparations containing them for the antagonists of tachycin IL124309A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL14532496A IL145324A0 (en) 1996-01-05 1996-12-09 Azetidinylalkyl derivatives of n-containing heterocyclic compounds, process for their preparation and a pharmaceutical composition containing them for antagonizing tachykinin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9600235.7A GB9600235D0 (en) 1996-01-05 1996-01-05 Therapeutic agents
PCT/EP1996/005613 WO1997025322A1 (fr) 1996-01-05 1996-12-09 3-azetidinylalkylpiperidines ou -pyrrolidines en tant qu'antagonistes des tachykinines

Publications (2)

Publication Number Publication Date
IL124309A0 IL124309A0 (en) 1998-12-06
IL124309A true IL124309A (en) 2002-11-10

Family

ID=10786682

Family Applications (2)

Application Number Title Priority Date Filing Date
IL12430996A IL124309A (en) 1996-01-05 1996-12-09 Aztidinylalkyl derivatives of the N-heterocyclic compounds, the process for their preparation and medicinal preparations containing them for the antagonists of tachycin
IL14532496A IL145324A0 (en) 1996-01-05 1996-12-09 Azetidinylalkyl derivatives of n-containing heterocyclic compounds, process for their preparation and a pharmaceutical composition containing them for antagonizing tachykinin

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL14532496A IL145324A0 (en) 1996-01-05 1996-12-09 Azetidinylalkyl derivatives of n-containing heterocyclic compounds, process for their preparation and a pharmaceutical composition containing them for antagonizing tachykinin

Country Status (38)

Country Link
US (1) US6242438B1 (fr)
EP (1) EP0871623B1 (fr)
JP (2) JP3123611B2 (fr)
KR (1) KR100275402B1 (fr)
AP (1) AP709A (fr)
AR (2) AR005339A1 (fr)
AT (1) ATE232526T1 (fr)
AU (1) AU708282B2 (fr)
BG (1) BG102589A (fr)
BR (1) BR9612412A (fr)
CA (1) CA2237189C (fr)
CO (1) CO4750815A1 (fr)
CZ (1) CZ209398A3 (fr)
DE (1) DE69626220T2 (fr)
DK (1) DK0871623T3 (fr)
DZ (1) DZ2155A1 (fr)
ES (1) ES2190486T3 (fr)
GB (1) GB9600235D0 (fr)
HR (1) HRP970006A2 (fr)
HU (1) HUP9903590A3 (fr)
IL (2) IL124309A (fr)
IS (1) IS1876B (fr)
MA (1) MA26417A1 (fr)
NO (1) NO311838B1 (fr)
NZ (1) NZ324712A (fr)
OA (1) OA10863A (fr)
PE (1) PE29798A1 (fr)
PL (1) PL185723B1 (fr)
RU (1) RU2158264C2 (fr)
SI (1) SI0871623T1 (fr)
SK (1) SK89598A3 (fr)
TN (1) TNSN96174A1 (fr)
TR (1) TR199801268T2 (fr)
TW (1) TW472054B (fr)
UY (1) UY24429A1 (fr)
WO (1) WO1997025322A1 (fr)
YU (1) YU71496A (fr)
ZA (1) ZA9747B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9714129D0 (en) 1997-07-04 1997-09-10 Pfizer Ltd Azetidines
AU1089599A (en) * 1997-10-15 1999-05-03 Coelacanth Chemical Corporation Synthesis of azetidine derivatives
ATE297906T1 (de) 1997-12-04 2005-07-15 Sankyo Co Alicyclische acylierte heterocyclenderivate
GB9821898D0 (en) * 1998-10-08 1998-12-02 Pfizer Ltd Heterocycles
AU2001275524B2 (en) * 2000-06-12 2006-02-02 University Of Rochester Method of treating symptoms of hormonal variation, including hot flashes, using tachykinin receptor antagonist
US6642226B2 (en) 2001-02-06 2003-11-04 Hoffman-La Roche Inc. Substituted phenyl-piperidine methanone compounds
GB0130261D0 (en) 2001-12-18 2002-02-06 Pfizer Ltd Lactams as tachykinin antagonists
US7674783B2 (en) * 2002-11-22 2010-03-09 Dimera Inc. Estrogen beta receptor agonists to prevent or reduce the severity of cardiovascular disease
AU2003299249B2 (en) * 2002-12-23 2010-05-27 Janssen Pharmaceutica N.V. Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
TW200508221A (en) 2003-06-13 2005-03-01 Astrazeneca Ab New azetidine compounds
WO2006012226A2 (fr) * 2004-06-24 2006-02-02 Incyte Corporation Piperidines a substitution n et utilisation de ces dernieres en tant que substances pharmaceutiques
CA2589565A1 (fr) * 2004-06-24 2006-01-05 Incyte Corporation Composes amido et leur utilisation en tant que produits pharmaceutiques
CA2599186C (fr) 2005-03-08 2014-12-09 Janssen Pharmaceutica N.V. Derives de diaza-spiro-[4.4]-nonane en tant qu'antagonistes de neurokinines (nk1)
AR057828A1 (es) 2005-09-29 2007-12-19 Astrazeneca Ab Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica
US8106208B2 (en) 2006-05-18 2012-01-31 Albireo Ab Benzamide compounds that act as NK receptor antagonists
JP2010516734A (ja) 2007-01-24 2010-05-20 グラクソ グループ リミテッド ３，５−ジアミノ−６−（２，３−ジクロロフェニル）−１，２，４−トリアジンまたはｒ（−）−２，４−ジアミノ−５−（２，３−ジクロロフェニル）−６−フルオロメチルピリミジンを含む医薬組成物
TW201026666A (en) * 2008-12-16 2010-07-16 Astrazeneca Ab Quaternary piperidine derivatives and uses thereof
JP2012524802A (ja) * 2009-04-22 2012-10-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ モノアシルグリセロールリパーゼ阻害剤としてのアゼチジニルジアミド

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2676055B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
DE69405862T2 (de) * 1993-05-06 1998-01-15 Merrell Pharma Inc Substituierte pyrrolidin-3-alkyl-piperidine verwendbar als tachykinin-antagonisten
FR2719311B1 (fr) * 1994-03-18 1998-06-26 Sanofi Sa Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic.
TW432061B (en) 1994-08-09 2001-05-01 Pfizer Res & Dev Lactams
GB9601202D0 (en) * 1996-01-22 1996-03-20 Pfizer Ltd Piperidones
GB9812037D0 (en) * 1998-06-04 1998-07-29 Pfizer Ltd Piperidones
GB9821898D0 (en) * 1998-10-08 1998-12-02 Pfizer Ltd Heterocycles

Also Published As

Publication number Publication date
NO982651L (no) 1998-06-09
DE69626220D1 (de) 2003-03-20
AR005338A1 (es) 1999-04-28
KR19990077027A (ko) 1999-10-25
AU708282B2 (en) 1999-07-29
HRP970006A2 (en) 1998-06-30
JP3123611B2 (ja) 2001-01-15
BG102589A (en) 1999-09-30
DZ2155A1 (fr) 2002-10-26
CA2237189C (fr) 2002-09-03
SI0871623T1 (en) 2003-08-31
PL327665A1 (en) 1998-12-21
IL124309A0 (en) 1998-12-06
IS4760A (is) 1998-05-28
UY24429A1 (es) 2001-08-27
HUP9903590A2 (hu) 2000-05-28
PE29798A1 (es) 1998-06-11
NO982651D0 (no) 1998-06-09
EP0871623B1 (fr) 2003-02-12
AR005339A1 (es) 1999-04-28
ES2190486T3 (es) 2003-08-01
TNSN96174A1 (fr) 2005-03-15
RU2158264C2 (ru) 2000-10-27
US6242438B1 (en) 2001-06-05
NO311838B1 (no) 2002-02-04
EP0871623A1 (fr) 1998-10-21
IS1876B (is) 2003-05-28
BR9612412A (pt) 1999-07-13
KR100275402B1 (ko) 2000-12-15
YU71496A (en) 1999-11-22
ATE232526T1 (de) 2003-02-15
AP9600901A0 (en) 1997-01-31
PL185723B1 (pl) 2003-07-31
CA2237189A1 (fr) 1997-07-17
GB9600235D0 (en) 1996-03-06
DE69626220T2 (de) 2003-08-28
JP3254205B2 (ja) 2002-02-04
MA26417A1 (fr) 2004-12-20
CZ209398A3 (cs) 1999-04-14
IL145324A0 (en) 2002-06-30
AP709A (en) 1998-12-22
ZA9747B (en) 1998-09-30
WO1997025322A1 (fr) 1997-07-17
JP2000344741A (ja) 2000-12-12
DK0871623T3 (da) 2003-03-31
HUP9903590A3 (en) 2002-01-28
NZ324712A (en) 1999-05-28
OA10863A (en) 2001-09-27
CO4750815A1 (es) 1999-03-31
TW472054B (en) 2002-01-11
AU1195097A (en) 1997-08-01
JPH11501667A (ja) 1999-02-09
SK89598A3 (en) 2000-02-14
TR199801268T2 (xx) 1998-10-21

Similar Documents

Publication Publication Date Title
EP0775132B1 (fr) (azetidin-1-ylalkyl) lactames utilises comme antagonistes de la tachykinine
EP0862567B1 (fr) 5-azabicyclo(3,1,0)hexylalkyl-2-piperidones et -glutarimides en tant qu'antagonistes du recepteur des neurokinines
IL124309A (en) Aztidinylalkyl derivatives of the N-heterocyclic compounds, the process for their preparation and medicinal preparations containing them for the antagonists of tachycin
AP1110A (en) Azetidinylpropylpiperidine derivatives and use as tachykinin antagonist.
US6262075B1 (en) Piperidone tachykinin antagonists
US5846965A (en) 3-aza and 3-oxa piperidone tachykinin antagonists
US5741790A (en) Azetidines

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees